Accelerate Diagnostics (AXDX) Issues Quarterly Earnings Results
Accelerate Diagnostics (NASDAQ:AXDX) issued its quarterly earnings results on Thursday. The medical research company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.05, Bloomberg Earnings reports. Accelerate Diagnostics had a negative net margin of 3,085.36% and a negative return on equity of 60.99%. The firm had revenue of $2.10 million for the quarter.
Shares of Accelerate Diagnostics (NASDAQ AXDX) traded up $1.65 during mid-day trading on Friday, hitting $24.90. 281,000 shares of the stock were exchanged, compared to its average volume of 279,228. The company has a market cap of $1,287.99, a PE ratio of -20.33 and a beta of 2.20. Accelerate Diagnostics has a 12 month low of $16.75 and a 12 month high of $30.45.
Several equities research analysts have commented on AXDX shares. ValuEngine cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, February 9th. BTIG Research cut shares of Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 13th. They noted that the move was a valuation call. BidaskClub cut shares of Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Zacks Investment Research raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $33.00.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.